Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hengyu Biopharmaceutical
Shandong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Hengyu Biopharmaceutical leads the Chinese market in marine-derived nucleic acid (PDRN/PN) production with commercial-grade approval for medical devices, focusing on regenerative therapies and aesthetic medicine; it has completed a national industrial ecosystem for PDRN and is pursuing international expansion, including South Korea[1][2].
- Therapeutic areas
- OtherDermatologyRheumatology
- Modalities
- BiologicNucleic acidSmall moleculeMedical device
- Industry
- Biotech
02
Partnerships
Korean Medical Beauty (Sino-Korean joint venture in Shandong Free Trade Zone)MIGO aesthetic medicine institution
Beyond the preview
Go deeper on Hengyu Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hengyu Biopharmaceutical.